Updates Abound

Introduction GLP-1 RAs in Combination With Basal Insulin Approved by US FDA

Why Combine a GLP-1 RA With Basal Insulin?

Adding Prandial Insulin to Basal Insulin

Exenatide Once Weekly Now Approved for Use With Basal Insulin

Exenatide QW + Insulin Reduced HbA1c and Body Weight Compared With Placebo + Insulin

Uptitration of Basal Insulin Dose or Intensification for Prandial Control

AACE/ACE Recommendations for Adding/Intensifying Insulin

Patient Satisfaction With GLP-1 RAs

Introduction: SGLT2 Inhibitors in Combination With Basal Insulin

DURATION-8 Combining Exenatide QW and Dapagliflozin vs Exenatide or Dapagliflozin in Patients With T2D on Metformin

DURATION-8 Change in HbA1c

Practicality in Clinical Practice

GLP-1 RA in Combination With an SGLT2 Inhibitor

New Data From DURATION-8 Presented at ADA 2018 Scientific Sessions

Weight, SBP, and Safety

The Increasing Role of GLP-1 RAs and SGLT2 Inhibitors for T2D

Concluding Remarks

Abbreviations

Abbreviations (cont)